Diminished monocytic HLA-DR expression and ex vivo cytokine secretion capacity in patients with glioblastoma: Effect of tumor extirpation

Journal of Neuroimmunology

Volumn 84, Issue 2, 1998, Pages 164-171

  Woiciechowsky, Christian ^a   Asadullah, Khusru ^b   Nestler, Dirk ^a   Schöning, Britta ^a   Glöckner, Frauke ^a   Döcke, Wolf Dietrich ^b   Volk, Hans Dieter ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Glioblastoma; HLA DR; IL 10; Immunodepression; Monocytes; TGF ; TNF

Indexed keywords

CORTICOTROPIN; CYTOKINE; HLA DR ANTIGEN; HYDROCORTISONE; INTERLEUKIN 10; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOLOGY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; GLIOBLASTOMA; HLA SYSTEM; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; PRIORITY JOURNAL;

ADRENOCORTICOTROPIC HORMONE; ADULT; AGED; BRAIN NEOPLASMS; CYTOKINES; ENDOTOXINS; FEMALE; GLIOBLASTOMA; HLA-DR ANTIGENS; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INTERLEUKIN-10; MALE; MIDDLE AGED; MONOCYTES; PITUITARY-ADRENAL SYSTEM; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032522113     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00236-1     Document Type: Article

References (48)

1. Asadullah K., Woiciechowsky C., Döcke W.D., Egerer K., Kox W., Vogel S., Sterry W., Volk H.D. Very low monocytic HLA-DR expression indicates high risk of infection - immunomonitoring for patients after neurosurgery and patients during high dose steroid therapy. Eur. J. Emerg. Med. 2:1995;184-190.
2. Asadullah K., Woiciechowsky C., Döcke W.D., Liebenthal C., Wauer H., Volk H.D., Kox W., Vogel S., von Baehr R. Immunodepression following neurosurgical procedures. Crit. Care Med. 23:1995;1976-1983.
3. Black K.L., Chen K., Becker D.P., Merrill J.E. Inflammatory leukocytes associated with increased immunosuppression by glioblastoma. J. Neurosurg. 77:1992;120-126.
4. Bodmer S., Huber D., Heid I., Fontana A. Human glioblastoma cell derived transforming growth factor-beta 2: evidence for secretion of both high and low molecular weight biologically active forms. J. Neuroimmunol. 34:1991;33-42.
5. Bogdan C., Nathan C. Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10. Ann. N.Y. Acad. Sci. 685:1993;713-739.
6. Brooks W.H., Netsky M.G., Normansell D.E., Horwitz D.A. Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J. Exp. Med. 136:1972;1631-1647.
7. Cheadle W.G., Hershman M.J., Wellhausen S.R., Polk H.C. HLA-DR antigen expression on peripheral blood monocytes correlates with surgical infection. Am. J. Surg. 161:1991;639-645.
8. Constam D.B., Philipp J., Malipiero U.V., ten Dijke P., Schachner M., Fontana A. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J. Immunol. 148:1992;1404-1410.
9. Czarniecki C.W., Chiu H.H., Wong G.H., McCabe S.M., Palladino M.A. Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells. J. Immunol. 140:1988;4217-4223.
10. D'Andrea A., Aste Amezaga M., Valiante N.M., Ma X., Kubin M., Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med. 178:1993;1041-1048.
11. de Waal Malefyt R., Abrams J., Bennett B., Figdor C.G., de Vries J.E. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174:1991;1209-1220.
12. de Waal Malefyt R., Haanen J., Spits H., Roncarolo M.G., te Velde A., Figdor C., Johnson K., Kastelein R., Yssel H., de Vries J.E. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 174:1991;915-924.
13. Donnet Hughes A., Schiffrin E.J., Huggett A.C. Expression of MHC antigens by intestinal epithelial cells. Effect of transforming growth factor-beta 2 (TGF-beta 2). Clin. Exp. Immunol. 99:1995;240-244.
14. Döcke, W.D., Syrbe, U., Meinecke, A., Platzer, C., Makki, A., Asadullah, K., Klug, C., Zuckermann, H., Reinke, P., von Baehr, R., Volk, H.D., 1994. Improvement of monocyte function - A new therapeutic approach. In: Reinhart, K., Eyrich, K., Sprung, C. (Eds.), Sepsis - Current perspectives in pathophysiology and therapy, Springer, Berlin, Heidelberg, pp. 473-500.
15. Döcke, W.D., Platzer, C., Syrbe, U., Meisel, C., Zuckerman, H., Klug, C., von Baehr, R., Volk, H.D., 1996. Monocytic deactivation in fatal septic disease - Role of tumor necrosis factor-alpha and interleukin-10. In: Faist, E., Baue, A., Schildberg, F. (Eds.), MOF, MODS and SIRS. Basic mechanisms in inflammation and tissue injury, Pabst Science Publishers, Lengerich, pp. 162-168.
16. Döcke W.D., Randow F., Syrbe U., Krausch D., Asadullah K., Reinke P., Volk H.D., Kox W. Monocyte deactivation in septic patients: Restoration by IFN-g treatment. Nature Med. 3:1997;678-681.
17. Elliott L.H., Brooks W.H., Roszman T.L. Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors. J. Immunol. 132:1984;1208-1215.
18. Elliott L.H., Brooks W.H., Roszman T.L. Activation of immunoregulatory lymphocytes obtained from patients with malignant gliomas. J. Neurosurg. 67:1987;231-236.
19. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147:1991;3815-3822.
20. Gibbons R.A., Martinez O.M., Lim R.C., Horn J.K., Garovoy M.R. Reduction in HLA-DR, HLA-DQ and HLA-DP expression by Leu-M3+ cells from the peripheral blood of patients with thermal injury. Injury. 19:1989;263-266.
21. Guillou P.J. Biological variation in the development of sepsis after surgery or trauma. Lancet. 342:1993;217-220.
22. Hershman M.J., Cheadle W.G., Wellhausen S.R., Davidson P.F., Polk H.C. Monocyte HLA-DR antigen expression characterizes clinical outcome in the trauma patient. Br. J. Surg. 77:1990;204-207.
23. Huettner C., Paulus W., Roggendorf W. Increased amounts of IL-10 mRNA in anaplastic astrocytomas and glioblastoma multiforme. Verh. Dtsch. Ges. Pathol. 78:1994;418-422.
24. Janeway C.C., Bottomly K., Babich J. Quantitative variation in Ia antigen expression plays a central role in immune regulation. Immunol. Today. 5:1984;99-105.
25. Junkins J.M., Beveridge R.A., Friedman K.J. An unusual fungal infection in an immunocompromised oncology patient. Cutaneous alternariosis. Arch. Dermatol. 124:1988;1424-1425.
26. Kuppner M.C., Hamou M.F., Sawamura Y., Bodmer S., de Tribolet N. Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2. J. Neurosurg. 71:1989;211-217.
27. Nitta T., Hishii M., Sato K., Okumura K. Selective expression of interleukin-10 gene within glioblastoma multiforme. Brain Res. 649:1994;122-128.
28. Olofsson A., Miyazono K., Kanzaki T., Colosetti P., Engstrom U., Heldin C.H. Transforming growth factor-beta 1, -beta 2, and -beta 3 secreted by a human glioblastoma cell line. Identification of small and different forms of large latent complexes. J. Biol. Chem. 267:1992;19482-19488.
29. Peterson P.K., Chao C.C., Hu S., Thielen K., Shaskan E.G. Glioblastoma, transforming growth factor-beta, and Candida meningitis: a potential link. Am. J. Med. 92:1992;262-264.
30. Randow F., Syrbe U., Meisel C., Krausch D., Zuckermann H., Platzer C., Volk H.D. Mechanism of endotoxin desensitization: Involvement of interleukin 10 and transforming growth factor beta. J. Exp. Med. 181:1995;1887-1892.
31. Reichlin S. Neuroendocrine-immune interactions. N. Engl. J. Med. 329:1993;1246-1253.
32. Reimold A.M., Kara C.J., Rooney J.W., Glimcher L.H. Transforming growth factor beta 1 repression of the HLA-DR alpha gene is mediated by conserved proximal promoter elements. J. Immunol. 151:1993;4173-4182.
33. Roszman T.L., Brooks W.H., Elliott L.H. Inhibition of lymphocyte responsiveness by a glial tumor cell-derived suppressive factor. J. Neurosurg. 67:1987;874-879.
34. Sasaki A., Naganuma H., Satoh E., Nagasaka M., Isoe S., Nakano S., Nukui H. Secretion of transforming growth factor-beta 1 and -beta 2 by malignant glioma cells. Neurol. Med. Chir. 35:1995;423-430.
35. Schmitt E., Hoehn P., Huels C., Goedert S., Palm N., Rude E., Germann T. T helper type 1 development of naive CD4+ T cells requires the coordinate action of interleukin-12 and interferon-gamma and is inhibited bu transforming growth factor-beta. Eur. J. Immunol. 24:1994;793-798.
36. Shugg D., Allen B.J., Blizzard L., Dwyer T., Roder D. Brain cancer incidence, mortality and case survival: observation from two Australian cancer registries. Int. J. Cancer. 59:1994;765-770.
37. Suberville S., Bellocq A., Fouqueray B., Philippe C., Lantz O., Perez J., Baud L. Regulation of interleukin-10 production by beta-adrenergic agonists. Eur. J. Immunol. 26:1996;2601-2605.
38. Tada M., de Tribolet N. Recent advances in immunobiology of brain tumors. J. Neurooncol. 17:1993;261-271.
39. Tada M., Diserens A.C., Desbaillets I., Jaufeerally R., Hamou M.F., de Tribolet N. Production of interleukin-1 receptor antagonist by human glioblastoma cells in vitro and in vivo. J. Neuroimmunol. 50:1994;187-194.
40. Urbani F., Maleci A., La Sala A., Lande R., Ausiello C.M. Defective expression of interferon-gamma, granulocyte-macrophage colony-stimulating factor, tumor necrosis factor alpha, and interleukin-6 in activated peripheral blood lymphocytes from glioma patients. J. Interferon Cytokine Res. 15:1995;421-429.
41. van der Poll T., Coyle S.M., Barbosa K., Braxton C.C., Lowry S.F. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxinemia. J. Clin. Invest. 97:1996;713-719.
42. Volk H.D., Reinke P., Falck P., Staffa G., Briedigkeit H., von Baehr R. Diagnostic value of an immune monitoring program for the clinical management of immunosuppressed patients with septic complications. Clin. Transplant. 3:1989;246-252.
43. Volk, H.D., Thieme, M., Heym, S., Döcke, W.D., Ruppe, U., Tausch, W., Manger, D., Zuckermann, S., Golosubow, A., Nieter, B. et al., 1991. Alterations in function and phenotype of monocytes from patients with septic disease-predictive value and new therapeutic strategies. Behring Inst. Mitt., 208-215.
44. Volk H.D., Reinke P., Krausch D., Zuckermann H., Asadullah K., Müller J.M., Döcke W.D., Kox W.J. Monocyte deactivation - rationale for a new therapeutic strategy in sepsis. J. Intensive Care Med. 22:1996;474-481.
45. Wakefield C.H., Carey P.D., Foulds S., Monson J.R., Guillou P.J. Changes in major histocompatibility complex class II expression in monocytes and T cells of patients developing infection after surgery. Br. J. Surg. 80:1993;205-209.
46. Wilson B.M., Severn A., Rapson N.T., Chana J., Hopkins P. A convenient human whole blood culture system for studying the regulation of tumour necrosis factor release by bacterial lipopolysaccharide. J. Immunol. Methods. 139:1991;233-240.
47. Yoshida J., Kajita Y., Wakabayashi T., Sugita K. Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumor resection and postoperative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir. Wien. 127:1994;55-59.
48. Zuckerman S.H., Shellhaas J., Butler L.D. Differential regulation of lipopolysaccharide-induced interleukin 1 and tumor necrosis factor synthesis: effects of endogenous and exogenous glucocorticoids and the role of the pituitary-adrenal axis. J. Immunol. 19:1989;301-305.